Annual Non Current Assets
$22.86 M
-$7.00 M-23.43%
December 31, 2023
Summary
- As of February 6, 2025, TSHA annual long term assets is $22.86 million, with the most recent change of -$7.00 million (-23.43%) on December 31, 2023.
- During the last 3 years, TSHA annual non current assets has risen by +$21.86 million (+2181.74%).
- TSHA annual non current assets is now -57.94% below its all-time high of $54.35 million, reached on December 31, 2021.
Performance
TSHA Non Current Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Non Current Assets
$18.66 M
-$3.26 M-14.87%
September 30, 2024
Summary
- As of February 6, 2025, TSHA quarterly long term assets is $18.66 million, with the most recent change of -$3.26 million (-14.87%) on September 30, 2024.
- Over the past year, TSHA quarterly non current assets has dropped by -$5.30 million (-22.12%).
- TSHA quarterly non current assets is now -72.74% below its all-time high of $68.47 million, reached on September 30, 2022.
Performance
TSHA Quarterly Non Current Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Non Current Assets Formula
Non Current Assets = Property, Plant, and Equipment + Intangible Assets + Long-Term Investments + Deferred Tax Assets + Other Non-Current Assets
TSHA Non Current Assets Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -23.4% | -22.1% |
3 y3 years | +2181.7% | -57.5% |
5 y5 years | +100.0% | - |
TSHA Non Current Assets Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -57.9% | at low | -72.7% | at low |
5 y | 5-year | -57.9% | -100.0% | -72.7% | >+9999.0% |
alltime | all time | -57.9% | -100.0% | -72.7% | >+9999.0% |
Taysha Gene Therapies Non Current Assets History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $18.66 M(-14.9%) |
Jun 2024 | - | $21.92 M(-2.1%) |
Mar 2024 | - | $22.40 M(-2.0%) |
Dec 2023 | $149.87 M(+55.4%) | $22.86 M(-4.6%) |
Sep 2023 | - | $23.96 M(-12.6%) |
Jun 2023 | - | $27.43 M(-6.2%) |
Mar 2023 | - | $29.24 M(-2.1%) |
Dec 2022 | $96.42 M | $29.86 M(-56.4%) |
Sep 2022 | - | $68.47 M(+4.5%) |
Jun 2022 | - | $65.50 M(+10.9%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2022 | - | $59.09 M(+8.7%) |
Dec 2021 | $159.60 M(-38.1%) | $54.35 M(+23.9%) |
Sep 2021 | - | $43.87 M(+27.0%) |
Jun 2021 | - | $34.56 M(+979.9%) |
Mar 2021 | - | $3.20 M(+219.4%) |
Dec 2020 | $257.88 M(>+9900.0%) | - |
Dec 2020 | - | $1.00 M(+3478.6%) |
Sep 2020 | - | $28.00 K(+47.4%) |
Jun 2020 | - | $19.00 K |
Dec 2019 | $15.00 K | - |
FAQ
- What is Taysha Gene Therapies annual long term assets?
- What is the all time high annual non current assets for Taysha Gene Therapies?
- What is Taysha Gene Therapies annual non current assets year-on-year change?
- What is Taysha Gene Therapies quarterly long term assets?
- What is the all time high quarterly non current assets for Taysha Gene Therapies?
- What is Taysha Gene Therapies quarterly non current assets year-on-year change?
What is Taysha Gene Therapies annual long term assets?
The current annual non current assets of TSHA is $22.86 M
What is the all time high annual non current assets for Taysha Gene Therapies?
Taysha Gene Therapies all-time high annual long term assets is $54.35 M
What is Taysha Gene Therapies annual non current assets year-on-year change?
Over the past year, TSHA annual long term assets has changed by -$7.00 M (-23.43%)
What is Taysha Gene Therapies quarterly long term assets?
The current quarterly non current assets of TSHA is $18.66 M
What is the all time high quarterly non current assets for Taysha Gene Therapies?
Taysha Gene Therapies all-time high quarterly long term assets is $68.47 M
What is Taysha Gene Therapies quarterly non current assets year-on-year change?
Over the past year, TSHA quarterly long term assets has changed by -$5.30 M (-22.12%)